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Abstract
Background: In colorectal carcinoma, extensive gene promoter hypermethylation is called the CpG island
methylator phenotype (CIMP). Explaining why studies on CIMP and survival yield conflicting results is essential.
Most experiments to measure DNA methylation rely on the sodium bisulfite conversion of unmethylated cytosines
into uracils. No study has evaluated the performance of bisulfite conversion and methylation levels from matched
cryo-preserved and Formalin-Fixed Paraffin Embedded (FFPE) samples using pyrosequencing.
Methods: Couples of matched cryo-preserved and FFPE samples from 40 colon adenocarcinomas were analyzed.
Rates of bisulfite conversion and levels of methylation of LINE-1, MLH1 and MGMT markers were measured.
Results: For the reproducibility of bisulfite conversion, the mean of bisulfite-to-bisulfite standard deviation (SD) was
1.3%. The mean of run-to-run SD of PCR/pyrosequencing was 0.9%. Of the 40 DNA couples, only 67.5%, 55.0%, and
57.5% of FFPE DNA were interpretable for LINE-1, MLH1, and MGMT markers, respectively, after the first analysis. On
frozen samples the proportion of well converted samples was 95.0%, 97.4% and 87.2% respectively. For DNA
showing a total bisulfite conversion, 8 couples (27.6%) for LINE-1, 4 couples (15.4%) for MLH1 and 8 couples (25.8%)
for MGMT displayed significant differences in methylation levels.
Conclusions: Frozen samples gave reproducible results for bisulfite conversion and reliable methylation levels. FFPE
samples gave unsatisfactory and non reproducible bisulfite conversions leading to random results for methylation
levels. The use of FFPE collections to assess DNA methylation by bisulfite methods must not be recommended.
This can partly explain the conflicting results on the prognosis of CIMP colon cancers.
Background
Epigenetic dysregulation is a major event in the origin of
many cancers [1]. DNA methylation, the most widely
studied epigenetic mechanism, occurs in cytosines that
precede guanines (CpG dinucleotides). The CpG dinu-
cleotides may be found concentrated in regions called
CpG islands, commonly located in gene promoters. In
colon cancers, a number of tumour suppressor genes
are transcriptionally silenced by promoter CpG island
hypermethylation [2,3]. Among them, one subset
referred to as the CpG island methylator phenotype
(CIMP) exhibits widespread promoter methylation [2,4].
Studies on CIMP status and survival in colon cancers
have yielded somewhat inconsistent results [5-13]. One
of our previous studies [5] as well as other studies
[8,11,13] suggested that the CIMP had an adverse effect
on survival in MSS (Microsatellite Stable) tumours,
while in other reports CIMP-H (CIMP-High) status was
independently associated with low specific mortality
[9,12]. These discrepancies might result from differences
i nt h ec h o i c eo ft i s s u es a m p l e s .T h eq u a l i t yo fD N A
samples depends especially on the material available
which may be cryo-preserved or formalin-fixed paraffin
embedded (FFPE) tissue. The cryo-preservation techni-
que provides the best protection of the DNA, but these
specimens are far less common than FFPE tissue from
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quality of archived specimens (FFPE tissues) depends on
the fixation and storage conditions employed and can
vary greatly from one sample to another. Moreover, for-
malin fixation induces degradation and cross-linkings
between proteins and proteins/DNA bases. FFPE tissues
thus produce a poorer yield of DNA. To evaluate DNA
methylation, the gold-standard method is based on
sodium bisulfite conversion [14], in which unmethylated
cytosines are converted into uracils. Then, after PCR, it
is possible to differentiate unmethylated cytosines
(replaced by thymines) from methylated cytosines which
are protected from bisulfite conversion [15]. However,
the DNA bisulfite conversion step is a chemical reaction
that also degrades DNA. All things considered, cross-
linkings and DNA degradation caused by fixation,
extraction and conversion methods have a negative
impact on conversion efficacy, while DNA conversion
must be total and reproducible to allow meaningful
interpretation of results.
A number of techniques have been employed to ana-
lyze converted DNA [16-19]. These include MSP
(methylation-specific polymerase chain reaction), Methy-
light (real time PCR), SMART-MSP (Sensitive Melting
Analysis after Real Time PCR - methylation-specific
polymerase chain reaction), MS-HRM (Methylation Sen-
sitive - High Resolution Melting) and pyrosequencing.
All these techniques are based on DNA bisulfite conver-
sion. Among them, pyrosequencing is the only one that
comprises an in-built measure to check the complete-
ness of bisulfite conversion (conversion control) which
allows a precise evaluation of the quality of the conver-
sion. Moreover, it gives the percentage of methylated
allele for each CpG dinucleotide analysed.
It is important to investigate why there are discrepan-
cies in the prognostic value of the CIMP phenotype in
colorectal cancers between studies especially as few
explanations have been proposed. The aim of this study
was to evaluate the feasibility of analyzing DNA methy-
lation from DNA extracted from FFPE tissues and to
compare the results with those obtained from frozen
material using pyrosequencing technology. To this end,
three different known markers of methylation (LINE-1,
MLH1 and MGMT) were chosen. Results of this work
could help establish a standard method for assessing
DNA methylation and thus make it possible to compare
results obtained in this field.
Methods
Samples
Forty tumour tissue samples from patients resected for a
colon adenocarcinoma were included. For each tumour,
o n ef r o z e ns a m p l ep r e v i o u s l ys t o r e di nt h eF e r d i n a n d
Cabanne Biological Resources Centre (Dijon, France)
and one FFPE (Formalin Fixed Paraffin Embedded) tis-
sue block, were available. The CPP EST I committee
(Comité de Protection des Personnes: Protection of
Individuals committee) approved the use of these biolo-
gical collections. The tissue samples were considered
surgical waste in accordance with French ethical laws
(L.1211-3 to L.1211-9).
Quality control of frozen samples was carried out
before DNA extraction according to a strict process.
Three sections, each separated by 15 other sections,
were cut on a cryostat and stained with Hematein-
Eosin-Safran (HES). These three stained sections were
analyzed by a pathologist and the proportion of tumour
tissue was recorded. The sections retained for the study
were the consecutive sections located between two
stained sections containing at least 40% of tumour cells.
The choice of the percentage of tumor cellularity was
established in our laboratory from previous analyses
(data not shown). This percentage was ample for methy-
lation quantification.
For FFPE samples, the slides were also reviewed by a
pathologist in order to select an area rich in tumour
cells (> 40% of tumour cells). The initial paraffin blocks
were manually dissected and the selected tumour area
was embedded in a new paraffin block.
For all pairs of FFPE/frozen samples, we always
checked that the difference in tumour cellularity
between selected sections was slight in order to be able
to compare both tissues.
DNA extraction from frozen tissues: Nucleospin
®96 tissue
kit (Macherey Nagel
®)
Twenty 50 μm-tissue sections were crushed with two
stainless steel balls in a mixture containing RLT buffer
(Qiagen
®)a n d1 %b-mercapto-ethanol (14.3 M; Sigma
Aldrich
®). Half of each sample was then centrifuged for
10 min (10000 rcf (relative centrifugal force)). The pel-
lets were suspended in 180 μl of lysis buffer (T1 buffer)
and 25 μl proteinase K. Samples were kept at 56°C over-
night. DNA extraction was performed with a TECAN
®
automate following the supplier’s recommendations.
DNA was released in 100 μl elution buffer.
DNA extraction from formalin-fixed paraffin embedded
(FFPE) tissues
Classical method
For each sample, ten 15 μm-thick tissue sections under-
went proteinase K digestion (> 600 mAU/ml, Qiagen
®)
at 56°C for one night. DNA was extracted using a Bio-
nobis kit (Magtration
®-Magazorb
®) and a Bionobis
®
automat according to the manufacturer’s instructions.
The samples were lysed, washed and then adsorbed
onto magnetic silicate particles. DNA was immobilized
by magnetic attraction, washed again and released in
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analyzed for the LINE-1 marker.
Dedicated Method to FFPE tissue: QIAamp
® DNA FFPE
Tissue kit (QIAGEN
®)
For each sample, ten 15-μm-thick tissue sections were
transferred into a 1.5 ml tube. The extraction was per-
formed according to the manufacturer’s protocol. For
further details see Additional file 1. In brief, tissue sec-
tions were first dewaxed using toluene and lysed under
denaturing conditions with proteinase K. Then lysates
were incubated at 90°C. DNA was bound to the mem-
brane and contaminants were washed away by several
washing steps. Finally pure DNA was eluted.
Quantification and quality assessment of DNA
DNA was quantified with a Nanodrop
® spectrophot-
ometer (Thermo scientific
®)a n dd i l u t e da t5 0n g / μl.
The quality of the DNA was assessed by multiplex PCR
which amplified microsatellite regions as previously
described [20,21].
DNA bisulfite conversion - EpiTect Bisulfite kit (QIAGEN
®)
For bisulfite conversion, the optimal quantity of DNA
was determined in a preliminary work (data not shown).
Five hundred nanograms of genomic DNA of each sam-
ple were used and bisulfite treatment was performed
according to the manufacturer’s protocol. For further
details see Additional file 1. In brief, first the bisulfite
mediated conversion of unmethylated cytosines was per-
formed. After, the converted single strand DNA was
bound to the membrane of the EpiTect spin columns.
Membrane bound DNA was washed, then desulfonated,
and washed again to remove the desulfonation agent.
Finally pure converted DNA was eluted.
PCR and pyrosequencing assays
We previously optimized PCR conditions for each
amplification by testing the following conditions: anneal-
ing temperature, magnesium concentration and cycle
number.
Measurement of LINE-1 methylation level
LINE-1 PCR amplifies a 154 base-pair sequence in the
consensus promoter of LINE-1 elements (acc. n°
X58075). It was performed using custom primers (Addi-
tional file 2), designed with the PyroMark assay design
2.0 (Qiagen
®). The PCR reaction was carried out in a 50
μL final volume comprising 25 μL of PyroMark Master
Mix (containing PCR buffer, dNTP and HotStar Taq
DNA polymerase), 5 μL of Coral Load buffer, 4 μLo f
25 mM MgCl2,1μL of the forward and biotinylated
reverse primers (0.2 μM final concentration), 13 μLo f
RNase free water and 1 μL of bisulfite treated DNA
(Qiagen
®). PCR cycling conditions were as follows:
initial denaturing at 95°C for 15 min, 45 cycles of 95°C
for 30 s, 56°C for 30 s, and 72°C for 30 s and final
extension at 72°C for 10 min. Reverse single-stranded
biotinylated templates were isolated using the PyroMark
Vacuum Prep WorkStation (Qiagen
®). Forty-six micro-
litres of PCR product were added to 38 μLo fb i n d i n g
buffer (Qiagen
®)a n d2μL streptavidin sepharose high-
performance beads (GE Healthcare
®). The mixtures
were shaken for 10 min at 1400 rpm (revolution per
minute). After agitation, beads covered by biotinylated
DNA were collected and retained on filter probes by
permanent vacuum. The filter probes were successively
immerged in different baths: in ethanol 70% for 5 s, in
PyroMark denaturation solution for 5 s and in Pyro-
Mark wash buffer 1× for 15 s (Qiagen
®). Then the
vacuum was turned off and the beads fixing DNA
strands were released into a 24 well plate containing 25
μl of annealing buffer with 0.3 μM of sequencing primer
in each well. The sequencing plate was kept at 80°C for
2 min and at room temperature for 5 min. Pyrosequen-
cing reactions were performed in a PyroMark Q24 MDx
system using PyroGold reagents (Qiagen
®). The nucleo-
tide dispensation order used is indicated in Additional
file 2. Results were analyzed using PyroMark Q24 2.0.6
Software. To ensure successful bisulfite conversion of
unmethylated cytosines, an internal conversion control
that corresponded to the position of a non-CG cytosine
(not subject to methylation) was present in the dispen-
sation sequence. The average LINE-1 methylation level
was calculated as the mean of the proportions of C (%)
at the 3 CpG sites analysed, which were located at posi-
tions +319, +322 and +329 (positions of the correspond-
ing Guanine in the forward DNA strand, in relation to
the first nucleotide base of the consensus promoter
sequence) and this indicated the level of methylation of
LINE-1 elements.
Measurement of MLH1 and MGMT methylation levels
To investigate the methylation level of MLH1 and
MGMT genes, we used the PyroMark Q24 kits (Qia-
gen
®) as we did not succeed in designing amplicons tar-
geting the same CpG sites with a smaller length than
those proposed in these kits. The MLH1 kit was
designed to detect the methylation level in a region -209
to -181 from the transcription start site of the MLH1
gene and the MGMT kit to detect the methylation level
in a region +17 to +39 in exon 1 of the MGMT gene.
PCR reactions were performed according to the manu-
facturer’s instructions. Then, 22 μL of PCR product was
added to 40 μLo fb i n d i n gb u f f e r ,1 6μL of ultrapure
water and 2 μL of streptavidin sepharose high-perfor-
mance beads. The single-stranded biotinylated templates
were purified similarly to the LINE-1 assay (mentioned
above). The sequencing plate containing purified DNA
strands and sequencing primer was kept at 80°C for 2
min and at room temperature for 5 min.
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Mark Q24 MDx system using PyroGold reagents (Qia-
gen
®). The nucleotide dispensation orders of MLH1 and
MGMT assays are indicated in Additional file 2. Results
were analyzed using PyroMark Q24 2.0.6 Software. To
ensure successful bisulfite conversion of unmethylated
cytosines, an internal conversion control that corre-
sponded to the position of a non-CG cytosine (not sub-
ject to methylation) was present in the dispensation
sequence. The average methylation level for the two
markers was calculated as the mean of the proportions
of C (%) at the 5 CpG sites that were analysed.
Assessment of reproducibility of bisulfite conversion,
PCR/Pyrosequencing
The reproducibility of bisulfite conversion efficiency and
PCR/Pyrosequencing and the variability of methylation
measurement generated using the same frozen DNA
sample were evaluated as shown in Figure 1. In practice,
a pool of tumour DNA from cryo-preserved tissues was
used; identical bisulfite conversions were performed one
day apart (day 1: conversion A, day 2: conversion B).
Four conversions were carried out on day 1 (A1, A2,
A3, A4) and two on day 2 (B1 and B2). Then, two inde-
pendent PCRs (one day apart) were carried out in dupli-
cate from each converted sample and then two
independent pyrosequencing procedures, one day apart,
were also performed. We measured the level of LINE-1
methylation for the three sites by pyrosequencing on
each of these 24 PCR products [six converted DNA
samples × two PCR × 2 (in duplicate)]. For each case
and each site we measured the standard deviations (SD)
on A1 through B2 of the four measures of levels of
methylation, which could primarily depend on variations
in bisulfite conversion. The repetition of PCR and Pyro-
sequencing allowed us to determine the exact levels of
methylation on the set of bisulfite-converted DNA sam-
ples. The SD calculated between the different measures
of methylation of each site for each given converted
sample could primarily depend on day-to-day variations
in the pyrosequencing assay. In addition, the maximum
variation in the methylation level in absolute value was
calculated for each site.
Results
Variability of measurement of the methylation level of
DNA from cryo-preserved tissue
Data for LINE-1 methylation levels of the pool of
tumour DNA sample for the three CpG sites analyzed
are summarized in Table 1. The mean of SDs observed
after bisulfite treatments (bisulfite-to-bisulfite SD) was
1.3% and the mean of SDs observed after PCR/pyrose-
quencing was 0.9%. The variability of measurement of
the methylation level induced by bisulfite conversion
Figure 1 Schematic representation of the procedure for evaluating methylation variability, by pyrosequencing, from cryo-preserved
tissue DNA. A1, A2, A3 and A4 symbols were the four replicates of the bisulfite conversion A of the pool of tumour DNA performed on day 1,
and B1 and B2 the two replicates of the bisulfite conversion B performed on day 2. PCR 1 and 2 were two similar but independent PCRs
performed one day apart in duplicate. Pyrosequencing 1 and 2 were two similar but independent pyrosequencing procedures performed one
day apart.
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site 2 and 1.4% for site 3.
Qualitative analysis of bisulfite conversion for FFPE
tissues
Classical extraction method
For DNA extracted with the classical method, the bisul-
fite conversion was tested for the LINE-1 marker.
Twenty five DNA samples displayed an uncertain
("check": 5.0 to 7.0% of unconverted cytosines) or poor
conversion ("failed": more than 7.0% of unconverted
cytosines) in the first analysis and 24 in the second ana-
lysis. The results of the control of conversion were not
always similar in the two analyses. Cases n° 2, 5, 6, 9,
14, 27 and 37 showed invalid control of conversion
("check” or “failed”) during the first analysis and valid
control ("passed": less than 5.0% of unconverted cyto-
sines) of conversion during the second analysis. On the
other hand, six cases (n° 8, 18, 20, 22, 23) showed valid
conversion after the first assay and invalid control of
conversion at the second analysis. For nine cases (n° 3,
16, 24, 28, 30, 32, 33, 36, 38) the controls showed valid
conversion for the two analyses. By combining the valid
results of the two analyses, 55.0% of the cases (22 cases)
were interpretable.
Dedicated extraction kit for the LINE-1 marker
All the DNAs could be amplified. The internal controls
showed valid conversion for 27 cases (67.5%) in the first
analysis and 28 cases (70.0%) after the second analysis
with the LINE-1 marker. Cases n° 2, 11 and 19 showed
invalid control of conversion ("check” or “failed”)i nt h e
first analysis and valid control of conversion ("passed”)
in the second analysis. On the other hand, two cases (n°
4, 39) showed successful conversion after the first assay
and an invalid control of conversion in the second ana-
lysis. By combining the valid results of the two analyses,
75.0% of the cases were interpretable (30 of the 40 FFPE
DNAs).
Dedicated extraction kit for MLH1 and MGMT
With the MLH1 marker, 11 (27.5%) DNAs could not be
amplified. Among those that were amplified (29/40),
controls showed valid conversion for 23 cases (57.5% of
the 40 cases) in the first assay and 27 after combining
the two analyses. Concerning the MGMT marker, all
the DNAs could be amplified. The internal controls of
conversion were valid for 22 cases (55.0%) in the first
analysis. Among the 18 cases which gave an invalid con-
trol of conversion, 13 (n° 4, 7, 17, 19, 20, 22, 26, 30, 33,
34, 35, 39 and 40) gave a valid control of conversion in
the second analysis. By combining the valid results, 35
of the 40 (87.5%) FFPE DNAs showed valid control of
conversion.
Qualitative analysis of bisulfite conversion for cryo-
preserved tissues
The results of bisulfite conversion for the three markers
after two analyses are given in Table 2. Assessment of
the LINE-1 marker showed that two frozen samples
failed to be converted (cases 19 and 27) in the first
assay (95.0% of well converted DNA) and one was not
amplified after the two analyses (case 27). For the
MLH1 marker, in the first assay, only one DNA (n° 21)
Table 1 Variability of LINE-1 methylation levels of DNA from cryo-preserved tissue
converted
DNA samples
PCR 1 (% of methylation) PCR 2 (% of methylation) SD due to different
PCR and different
pyrosequencing
pyrosequencing 1 pyrosequencing 2 pyrosequencing 1 pyrosequencing 2
CpG
site 1
CpG
site 2
CpG
site 3
CpG
site 1
CpG
site 2
CpG
site 3
CpG
site 1
CpG
site 2
CpG
site 3
CpG
site 1
CpG
site 2
CpG
site 3
CpG
site 1
CpG
site 2
CpG
site 3
A1 55.9 62.9 62.3 55.0 62.1 62.2 56.5 61.6 59.3 54.6 63.4 61.4 0.9 0.8 1.4 mean
= 0.9
A2 53.1 63.1 59.7 56.0 63.3 59.5 53.2 62.7 60.0 57.5 62.3 60.5 2.2 0.4 0.4
A3 55.7 61.9 58.6 55.4 61.8 61.1 54.8 60.6 59.6 55.3 62.5 61.6 0.4 0.8 1.4
A4 54.1 63.8 60.7 56.4 63.6 59.9 56.4 63.7 60.3 55.8 64.1 59.6 1.1 0.2 0.5
B1 56.3 61.8 62.7 57.8 63.1 63.5 58.0 62.9 60.6 56.7 64.1 61.4 0.8 0.9 1.3
B2 55.9 63.4 62.9 57.9 64.0 63.2 55.2 63.1 62.5 58.6 64.7 63.3 1.6 0.7 0.4
bisulfite-to-
bisulfite SD
1.3 0.8 1.8 1.2 0.9 1.7 1.7 1.1 1.1 1.5 0.9 1.2
mean = 1.3
SD between all measures of site 1 1.4%
SD between all measures of site 2 1.0%
SD between all measures of site 3 1.4%
The levels of methylation (%) of the three studied CpG sites are given according to the converted DNA sample analysed (A1 through B2) and for each condition
of analysis (PCR and pyrosequencing). Numbers in bold italics indicate minimal values of methylation on all measures for each CpG site. Numbers in bold
indicate maximal values of methylation on all measures for each CpG site
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Identity FFPE DNA 1 FFPE DNA 2 FFPE DNA 2 FFPE DNA 2 Cryo. DNA Cryo. DNA Cryo. DNA
LINE-1 LINE-1 MLH1 MGMT LINE-1 MLH1 MGMT
PCR 1 PCR 2 PCR 1 PCR 2 PCR 1 PCR 2 PCR 1 PCR 2 PCR 1 PCR 2 PCR 1 PCR 2 PCR 1 PCR 2
1 check failed passed passed passed passed passed passed passed passed
2 failed passed check passed ⁄ passed passed passed passed passed
3 passed passed check check ⁄ failed failed passed passed passed passed
4 failed failed passed check ⁄ failed passed passed passed passed passed
5 failed passed failed check ⁄ passed passed passed passed passed passed passed
6 check passed passed passed passed passed passed passed passed passed
7 failed failed failed check passed passed failed passed passed passed passed check check
8 passed failed passed passed passed passed passed passed passed passed
9 check passed passed passed passed passed passed passed passed passed
10 failed failed passed passed passed passed passed passed passed passed
11 failed failed check passed ⁄ passed check check passed passed passed passed
12 failed failed failed check passed ⁄ passed check passed passed passed passed
13 check check passed passed passed passed passed passed passed passed
14 check passed passed passed ⁄ passed passed passed passed passed passed
15 check check passed passed passed passed passed passed passed passed
16 passed passed check check ⁄ passed passed passed passed passed passed passed
17 failed failed passed passed passed check passed passed passed passed passed
18 passed failed passed passed ⁄ passed passed passed passed passed
19 check failed failed passed ⁄ check passed check passed passed failed check
20 passed check passed passed passed failed passed passed passed passed passed
21 check check failed check ⁄ failed failed passed passed check failed passed
22 passed check check check passed failed passed passed passed passed passed
23 passed check passed passed passed passed passed passed passed passed
24 passed passed passed passed passed passed passed passed passed passed
25 passed failed passed passed ⁄ passed passed passed passed passed passed
26 check check passed passed passed check passed passed passed passed check check
27 check passed passed passed passed passed failed ⁄⁄ ⁄
28 passed passed passed passed passed failed failed passed passed passed passed
29 check check passed passed passed passed passed passed passed passed
30 passed passed passed passed failed check check passed passed passed passed passed
31 failed failed passed passed ⁄ passed passed passed passed passed
32 passed passed passed passed passed passed passed passed passed passed
33 passed passed check check passed ⁄ check passed passed passed passed passed
34 check check passed passed ⁄ failed passed passed passed passed passed
35 check failed passed passed ⁄ failed passed passed passed passed passed
36 passed passed passed passed failed failed passed passed passed passed passed
37 check passed check failed passed passed failed failed passed passed passed check check
38 passed passed check check passed passed passed passed passed passed failed failed
39 check check passed check passed check passed passed passed passed passed
40 check check passed passed ⁄ failed passed passed passed passed passed
From left to right the table gives results for DNA from FFPE tissues extracted with the classical method (FFPE DNA 1), extracted with the dedicated method (FFPE
DNA 2) and DNA from cryo-preserved tissues (Cryo. DNA). “Passed” indicates a good conversion (0.0 to 5.0% of unconverted cytosines). “Check” indicates an
uncertain conversion (5.0 to 7.0% of unconverted cytosines). “Failed” indicates a poor conversion (more than 7.0% of unconverted cytosines). Slash bar indicates
there was no amplification. Results in bold emphasize controls of conversion giving “check” or “failed” results.
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(97.4%) displayed satisfactory bisulfite conversion (DNA
n°27 was not amplified). The results were similar after
the second assay. For the MGMT marker, in the first
analysis, bisulfite conversion was not successful for five
cases (n°7, 19, 26, 37 and 38) and DNA n°27 was not
amplified. So 87.2% of cases showed valid controls of
conversion. The same results were obtained in the sec-
ond analysis.
Comparison of the controls of conversion obtained for
the three markers on the same DNA sample
The results of the conversion controls were not always
similar for a given DNA sample according to the marker
used. FFPE DNAs n° 5, 7, 12, 16, 22, 37 and 38 showed
good control of conversion with the MLH1 marker but
an uncertain or failed control of conversion with the
LINE-1 marker. Opposite results were observed for the
two FFPE DNAs n°30 and 36. When amplified for the
MGMT marker, FFPE DNAs n°5, 12, 16, 22, 33 and 38
showed good control of conversion but an uncertain or
failed control of conversion with the LINE-1 marker.
Opposite results were observed for the two FFPE DNAs
n°28 and 11. For cryo-preserved tissues, DNA n° 21 dis-
played a valid control of conversion for LINE-1 and
MGMT markers and an uncertain or failed control of
conversion when amplified for the MLH1 marker. Dur-
ing MGMT amplification, five DNAs (cases n°7, 19, 26,
37, 38) showed uncertain or failed controls of conver-
sion but valid controls of conversion for LINE-1 and
MLH1 markers.
Quantitative analysis of methylation levels for cryo-
preserved and FFPE tissues (DNA extracted with the
dedicated kit)
The methylation levels of the 40 couples of DNA
extracted from the same sample (cryo-preserved or
FFPE) for the three markers are given in Table 3. Con-
sidering our previous results on the variability of the
methylation level measure of DNA from cryo-preserved
tissues for the LINE-1 marker (Table 1), we selected the
minimal and maximal values of the methylation level for
each CpG site. We calculated the difference between the
two values to set up a threshold beyond which the dif-
ference in the methylation value was not due to the
variability of measurements. The differences were 5.6%
for CpG site 1, 4.1% for CpG site 2 and 4.9% of methy-
lation for CpG site 3. So we set an arbitrary threshold of
6.0% beyond which the difference was considered
significant.
We chose not to show methylation levels of FFPE
DNA extracted with the classical method because most
of these DNAs displayed invalid conversion. Neverthe-
less we noticed that these levels were often higher than
the levels of methylation of the same FFPE DNA
extracted with the dedicated kit because 40.0% of the
cases showed a significantly higher level of methylation
(Additional file 2).
Eight couples (n°10, 11, 13, 18, 19, 25, 28 and 29) pre-
sented a difference in LINE-1 methylation greater than
+6.0% or lower than -6.0% between cryo-preserved and
FFPE tissue. For these eight cases, the bisulfite conver-
sion control was successful for all cryo-preserved and
FFPE DNAs. Among these eight couples, the level of
methylation in five cases was higher for DNA extracted
from cryo-preserved tissue than from FFPE tissue and
lower in three cases. For the MLH1 marker, the differ-
ences could be established on 29 couples of DNA. Four
couples (1, 9, 13 and 17) displayed a difference in the
MLH1 methylation level greater than +6.0% or lower
than -6.0% with no problem of bisulfite conversion.
Among these four couples, three had a level of MLH1
methylation that was higher in the DNA extracted from
cryo-preserved tissue. With the MGMT marker, 15 cou-
ples (n° 3, 4, 6, 7, 10, 11, 17, 19, 20, 24, 25, 26, 28, 32
and 37) of DNA presented a difference in the level of
MGMT methylation greater than +6.0% or lower than
-6.0%. Seven of these couples (cases n°
3,7,11,19,26,28,37) showed a problem of bisulfite conver-
sion for one of the two samples. Among the remaining
eight couples, the methylation level was higher for DNA
extracted from FFPE tissue in six cases (n°6, 10, 17, 20,
24 and 32) and lower for two cases (n° 4 and 25). By
combining the analyses of the methylation levels of the
three markers (Table 3), no couples of frozen/FFPE
DNA presented a difference in the methylation level for
the three markers at the same time. Five couples of
DNA (n°10,11,19,25 and 28) displayed a difference in
methylation levels for both LINE-1 and MGMT markers,
one couple (n°13) for LINE-1 and MLH1 markers and
one couple (n°17) for MLH1 and MGMT. Examples of
pyrograms for couples showing differences in methyla-
tion levels are presented in Figure 2.
Synthetic analysis of bisulfite conversion quality and
methylation levels for cryo-preserved and FFPE tissues for
the three markers (Table 4)
For the Line 1 marker, 29 couples had successful bisul-
fite conversion. Among these, eight (27.6%) displayed a
significant difference in the methylation levels while 21
couples showed no difference in the methylation levels
between cryo-preserved and FFPE samples. For the
MLH1 marker, 26 out of 28 couples for which DNA
could be amplified showed satisfactory control of bisul-
fite conversion. Among these, four (15.4%) displayed a
significant difference in the methylation levels while 22
couples showed no difference in the methylation levels
between cryo-preserved and FFPE samples. For the
Tournier et al. BMC Cancer 2012, 12:12
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Page 7 of 12Table 3 Differences in methylation levels for each couple of frozen/FFPE DNA according to the three markers
Identity Levels of LINE-1
methylation
(% of methylation)
Difference
of
methylation
Levels of MLH1
methylation
(% of methylation)
Difference
of
methylation
Levels of MGMT
methylation
(% of methylation)
Difference
of
methylation
DNA from cryo-
preserved
tissues
DNA from
FFPE
tissues
DNA from
cryo-preserved
tissues
DNA from
FFPE
tissues
DNA from
cryo-preserved
tissues
DNA from
FFPE
tissues
1 62.0 66.3 -4.3 51.5 57.7 -6.2 1.7 4.3 -2.6
2 66.1 67.2 -1.1 4.8 - - 2.0 6.0 -4.0
3 64.6 64.8 † -0.2 47.6 - - 57.5 71.9 ‡ -14.3
4 57.2 52.3 5.0 6.8 - - 55.8 49.3 6.5
5 61.6 64.2 † -2.6 5.3 1,7* 3.6 1.9 6.2 -4.2
6 47.5 49.2 -1.7 2.9 3.9 -1.0 38.6 46.1 -7.5
7 59.4 56.6 † 2.9 5.1 1.9 3.3 59.4 † 43.4 16.0
8 47.9 46.5 1.3 3.4 1,5* 1.9 1.7 5.7 -4.0
9 64.5 61.2 3.3 33.1 13.3 19.7 14.7 18.2 -3.5
10 61.4 54.1 7.3 5.6 1.4 4.2 19.2 32.3 -13.1
11 60.5 50.1 10.4 3.9 3,4* 0.6 19.8 35.6 † -15.8
12 60.2 62.2 † -2.0 4.1 2.8 1.3 2.0 5.1 -3.2
13 45.1 62.5 -17.5 45.2 2.6 42.7 2.1 4.3 -2.2
14 57.0 60.8 -3.8 3.0 7,1* -4.1 1.4 1.9 -0.5
15 59.2 63.2 -4.0 2.5 5.6 -3.1 1.4 4.9 -3.5
16 52.8 47.5 † 5.2 2.6 3,3* -0.7 1.6 5.9 -4.3
17 61.0 55.6 5.3 77.7 4.6 73.1 1.7 30.2 -28.5
18 59.6 53.5 6.2 4.8 - - 28.9 25.3 3.6
19 43.3 54.4 -11.2 2.2 - 73.9 † 62.2 11.7
20 61.7 57.6 4.1 4.6 3.5 1.1 15.7 25.2 -9.5
21 65.2 66.1 † -1.0 6.1 † - - 2.2 7.0 ‡ -4.8
22 50.9 49.1 † 1.8 3.5 3.3 0.3 1.9 6.8 -5.0
23 61.6 59.4 2.2 3.5 2.1 1.4 1.6 4.6 -2.9
24 59.3 58.0 1.4 2.4 3.5 -1.1 20.8 32.4 -11.7
25 61.7 71.0 -9.3 4.1 - - 31.7 1,9* 29.8
26 56.7 52.2 4.4 2.4 0.9 1.5 52.8 † 20.4 32.4
27 45.5 ‡ 44.3 1.3 - 5.9 - - 4.2 -
28 65.3 57.4 7.9 6.6 2,7* 3.9 41.8 25.2 ‡ 16.6
29 64.0 57.3 6.7 3.4 2,4* 1.0 2.2 3.3 -1.1
30 56.4 56.7 -0.3 11.5 7.3 4.3 3.9 5.3 -1.5
31 62.0 62.9 -1.0 32.8 - - 5.7 5.3 0.4
32 67.2 62.0 5.2 3.9 5.2 -1.2 19.0 51.8 -32.8
33 60.2 62.4 † -2.3 4.0 3.9 0.1 2.0 7.9 -5.9
34 62.0 61.7 0.3 3.6 - - 2.2 5.9 -3.7
35 56.9 53.3 3.5 3.8 - - 2.1 5.6 -3.5
36 40.5 41.1 -0.6 3.0 3.6 -0.6 1.7 5.2 -3.5
37 59.0 62.1 † -3.0 2.7 3.3 -0.6 88.3 † 73.1 ‡ 15.1
38 62.3 58.5 † 3.8 4.3 1.5 2.8 68.2 71.7 -3.5
39 50.4 53.2 -2.9 4.8 4.5 0.3 1.9 4.6 -2.7
40 36.2 34.7 1.5 3.1 - - 2.0 5.9 -4.0
Values of methylation levels correspond to the average level of methylation of the three CpG sites evaluated for LINE-1 and the five CpG sites evaluated for
MLH1 and MGMT. Data were collected using the pyrogram which had the best internal control of conversion.
*: indicates an uncertain result due to the low intensity of the pyrogram. †: indicates an uncertain conversion (5.0 to 7.0% of unconverted cytosines). ‡: indicates
a poor conversion (more than 7.0% of unconverted cytosines). Numbers in bold indicate a difference of methylation level outside the -6.0/+6.0% interval.
Differences in methylation levels were calculated by subtracting the level of methylation of the cryo-preserved sample from the level of methylation of the FFPE
sample.
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version. Among these, eight (25.8%) displayed a signifi-
cant difference in the methylation levels while 23
couples showed no difference in the methylation levels
between cryo-preserved and FFPE samples. All things
considered, five couples (n°8,14,15,23,39) displayed both
satisfactory control of conversion and no difference in
the methylation levels for the three markers.
Discussion
Epigenetic silencing of genes, mostly mediated by aber-
rant DNA methylation, is a mechanism of gene inactiva-
tion in patients with colorectal cancer [2]. Among the
loci that can undergo aberrant methylation in colorectal
cancer, one subgroup appears to become aberrantly
methylated as a specific group [2,4], a phenomenon
called the CpG island methylator phenotype (CIMP).
Results in the literature on CIMP status as a prognostic
factor for colon cancers remain controversial. These
conflicting results could result from differences in
patient cohorts, samples (the use of frozen or FFPE tis-
sues), analytical techniques, methylation markers
(different genes or the same genes but screened at dif-
ferent sites), primer sequences and criteria for CIMP. In
our study, we chose to focus on the impact of the pre-
analytical phase. A variety of assays to measure DNA
methylation have been developed for FFPE and frozen
tissues many of which rely on the bisulfite conversion of
unmethylated cytosines from tumour tissue into uracils.
However, the efficacy of sodium bisulfite treatment and
the measurement of methylation levels in FFPE samples
in one hand and in frozen samples on the other hand
have never really been compared and evaluated.
In this study, we assessed the quality of bisulfite con-
version as well as methylation levels for LINE-1, MLH1
and MGMT markers by pyrosequencing from 40 pairs
of FFPE and frozen samples. Pyrosequencing is particu-
larly useful because it provides resolution at the indivi-
dual nucleotide level and includes a conversion control
for each analysis. Assays targeting CpG islands of LINE-
1, MLH1 and MGMT were chosen since aberrant
methylation of this retro-transposon and these genes is
implicated in colon cancers. LINE-1 (long interspersed
nucleotide element-1) is a retro-transposable element of
Figure 2 Pyrograms of the LINE-1, MLH1 and MGMT methylation markers for different couples of frozen/FFPE DNA. Pyrograms of LINE-1
marker are those obtained for couple n° 10 (A and B) and for MLH1 and MGMT markers those for couples n°13 (C and D) and n°6 (E and F)
respectively. Arrows indicate positions of internal controls of conversion, demonstrating no residual cytosines at the non-CpG sites. Gray areas
indicate polymorphisms, between T/C, generated by bisulfite treatment. Level of methylation for a given CpG dinucleotide is reported above it
(gray square).
Table 4 Synthetic view of the bisulfite conversion quality and the equivalence of methylation levels
LINE-1 124 6 8 9 14 15 17 20 23 24 26 30 31 32 34 35 36 39 40
MLH1 5678 10 11 12 14 15 16 20 22 23 24 26 28 29 32 33 37 38 39
MGMT 12 5 8 91 2 1 3 14 15 16 18 22 23 29 30 31 33 34 35 36 38 39 40
In each line (according to the corresponding marker) the identities of couples of frozen/FFPE DNAs (designated as couple 1 through couple 40) displaying both
successful controls of bisulfite conversion and no differences in methylation levels are listed. Numbers in bold indicates couples displaying both a successful
control of bisulfite conversion and no differences in methylation levels for the three markers.
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Page 9 of 12DNA that is present in 15% of the human genome. It is
a surrogate marker of genome-wide DNA methylation
[18,22,23]. It is frequently hypomethylated in human
cancers [24,25]. In contrast, the two genes MLH1 (the
human homolog of the E. coli DNA mismatch repair
gene mutL) and MGMT (O6-Methylguanine DNA
methyltransferase) are hypermethylated in a number of
different cancers, including colorectal cancer [26-28].
We first demonstrated that bisulfite-to-bisulfite stan-
dard deviations of methylation levels (mean 1.3%) and
PCR/pyrosequencing run-to-run standard deviations of
methylation levels (mean 0.9%) were low and acceptable.
We chose to carry out the assays on frozen tissues to
avoid the potential impact of DNA degradation from
FFPE tissues. The results obtained for LINE -1 can be
extrapolated to any other validated methylated markers.
These assays allowed us to consider that our process of
bisulfite conversion and PCR/pyrosequencing is repro-
ducible and to establish an arbitrary threshold of 6.0%
beyond which the difference in methylation value was
not due to variability in the measurements.
To assess the quality of sodium bisulfite conversion
and the subsequent PCR/pyrosequencing assays, using
the LINE-1 marker, we evaluated conversion of 40 FFPE
DNAs extracted using a routine method. The results
were neither satisfactory nor reliable since only 15 cases
showed valid control of conversion after the first analy-
sis and 22 cases (55.0%) after combining the two ana-
lyses. We consequently decided to use a dedicated kit to
re-extract DNA from FFPE tissues and to extend the
assays to the two other markers. All the samples were
evaluated using the LINE-1 and MGMT markers: only
27 cases (67.5%) showed good control of bisulfite con-
version with the LINE-1 marker and 22 cases (55.0%)
with the MGMT marker in the first assay. In contrast,
with the MLH1 marker, in 11 cases amplification failed,
possibly because of the length of the MLH1 amplicon
(181 pb). Among the 29 amplifiable samples, 23 (57.5%
of the 40 cases) showed valid control of conversion in
the first analysis. Furthermore, the results were not the
same in the second analysis. It is thus clear that the
extraction phase should not be conducted using a rou-
tine process and must comprise a supplementary step of
heating to 90°C for 1 h to improve bisulfite conversion.
Even with this dedicated method, the rate of satisfacto-
rily converted samples was much lower for FFPE than
for frozen samples. In contrast, the proportion of satis-
factorily converted samples in the first assay on frozen
samples was 95.0% with LINE-1, 97.4% with MLH1 and
87.2% with MGMT. The results were reliable and similar
after the second analysis. Furthermore, we did not
encounter the problem of failed amplification (due to
amplicon length) found with the MLH1 marker on FFPE
tissues. DNA derived from FFPE is an extremely
valuable source of material for retrospective studies, but
is often highly degraded. When PCR-based methods are
used to study DNA methylation changes, it is necessary
to modify the DNA with sodium bisulfite to preserve
the DNA methylation information of the original tem-
plate, and this treatment may further damage the DNA.
Fragmentation of FFPE DNA is a real drawback, particu-
larly in DNA methylation studies based on methylation-
independent PCR: the design of the primers must be
conducted with the highest score, primers have to hybri-
dize out of the CpG islands, and amplicon length has to
be limited. It is highly required to respect these con-
straints when using pyrosequencing which is the only
technique allowing a real quantification of methylation.
In our study, FFPE DNAs (n°30 and 36), showed invalid
control of conversion with MLH1 and good control with
LINE-1 and MGMT. In addition, none of the FFPE DNAs
showing invalid control of bisulfite conversion with LINE-
1 (10 cases) showed invalid conversion with MLH1, while
in three cases (cases n°3, 21 and 37) the results coincided
with those of MGMT. As the efficacy of bisulfite conver-
sion appeared to be heterogeneous all along the DNA and
variable according to the analysed marker, we think that
percentages of bisulfite conversion differ from one cyto-
sine to another due to residual cross-linkings (even with
the 90°C heating step) leading to non-reproducible results
on FFPE samples with the three markers.
Thus, even when extraction methods dedicated to
FFPE tissue were used, problems occurred with bisulfite
conversion. The importance of successful bisulfite con-
version was underlined by a panel of experts who
reported that incomplete conversion of DNA was the
major cause of false-positive results in methylation ana-
lysis [29]. We chose not to evaluate the results of the
methylation levels obtained from FFPE DNA extracted
using the classical method because the number of unsa-
tisfactory conversions was too high, but it was clear that
poor bisulfite conversion led to overestimation of
methylation (Additional file 3: Figure 1). In order to
compare the methylation levels of cryo-preserved and
FFPE samples (DNA extraction with the dedicated kit),
we established an arbitrary threshold (6.0%) beyond
which differences in the methylation value were not due
to variability in the measurements. We demonstrated
that with LINE-1 eight pairs (27.6%), with MLH1,f o u r
pairs (15.4%), and with MGMT, eight pairs (25.8%) dis-
played significant differences in the methylation level.
These deviations in methylation levels between matched
FFPE and cryo-preserved samples cannot be due to dif-
ferences in tumour cellularity as we checked that they
were slight. In a previous work (data not published) we
evaluated the variations in methylation levels induced by
variations in tumor cellularity using the LINE-1 marker,
and we observed a maximal deviation of 3.6% of
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from the same sample. This argument is supported by
the study published by Irahara et al. [30] who compared
average methylation values for LINE-1 in macrodissected
colon cancers with those for matched Laser Capture
Microdissection specimens providing a pure collection
of tumor cells. They found no substantial effects of con-
taminating normal cells on LINE-1 methylation.
We found no pairs that showed a difference in methy-
lation level with all three markers and we were unable to
establish a trend for the differences in methylation levels
in FFPE versus frozen samples. Clearly these deviations
in methylation levels differentially impact according to
the analyzed marker. For MLH1 and MGMT markers, a
sample is considered as methylated whatever it displayed
20% or 50% of methylation. But for the LINE-1 marker,
several subgroups of methylation can be distinguished
and variations of methylation shown here can be critical
for the creation of these subgroups.
Our study is the first to compare the results obtained
for DNA extracted from FFPE and frozen tissues to
assess the feasibility of DNA methylation analysis using
pyrosequencing. Some authors maintain that sodium
bisulfite treatment is sufficiently precise and shows good
reproducibility on FFPE samples leading to reliable
assessment of methylation levels [19,31]. Nevertheless,
these authors did not perform comparative studies with
frozen material and used techniques such as Methylight
(real time PCR), SMART-MSP (Sensitive Melting Analy-
sis after Real Time PCR - methylation-specific polymer-
ase chain reaction), MS-HRM (Methylation Sensitive-
High Resolution Melting), without a built-in measure to
check the completeness of bisulfite conversion (conver-
sion control). Furthermore, to confirm that FFPE tissue
can be effectively used for high-throughput DNA methy-
lation analysis, Ogino et al. [31] used the alternative
method of protein expression by immunohistochemistry,
which is a surrogate indicator of DNA methylation.
Looking ahead, there is another source of variability
that should be investigated: bisulfite conversion methods
which vary according to laboratories. This point rein-
forces the need for standardization in this domain.
Conclusions
In conclusion, we demonstrated that the use of FFPE tis-
sues induces unsatisfactory and non-reproducible bisul-
fite conversion leading tou n r e l i a b l er e s u l t sf o r
methylation levels. In contrast, frozen samples give
reproducible results for sodium bisulfite conversion and
subsequent pyrosequencing assays have acceptable preci-
sion using a single analysis. There is clearly a need to
standardize the entire process of DNA methylation analy-
sis from the tissue preservation method to the technology
used to quantify methylation. Our results indicate that
using FFPE collections to evaluate the prognosis of CIMP
colon cancers by bisulfite methods partly contributes to
the discrepant data observed in this field. In light of these
results, we strongly recommend the use of DNA from
cryo-preserved tissue when performing bisulfite conver-
sion to study DNA methylation.
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the two LINE-1 analyses of the FFPE DNA n°2 extracted with the classical
method.
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